Clinical Features and Analysis in Pituitary Stalk Interruption Syndrome

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2024 Jun 3

PMID 38828392

Authors

Qiuxuan Guo

Jing Zhao

Shuang Yu

Affiliations

Soon will be listed here.

Abstract

Objective: Pituitary stalk interruption syndrome (PSIS) is characterized by the absence of pituitary stalk, pituitary hypoplasia, and ectopic posterior pituitary. Because the etiology and clinical cognition of PSIS remain elusive, we analyzed the clinical features of PSIS in Chinese patients.

Methods: A retrospective analysis was conducted on the clinical presentation, laboratory data, imaging examination, and management of 24 PSIS inpatients from our center over 10 years.

Results: Among the 24 PSIS patients, there were 22 males (91.7%) and 2 females (8.3%). Growth hormone deficiency was present in all 24 cases (100%), hypogonadism in 24 cases (100%), secondary adrenal insufficiency in 22 cases (91.2%), and hypothyroidism in 21 cases (87.5%). 20 cases (83.3%) of PSIS patients exhibited deficiencies in four anterior pituitary hormones, 3 cases (12.5%) exhibited deficiencies in three anterior pituitary hormones, and 1 case (4.2%) exhibited deficiencies in two anterior pituitary hormones, with none exhibiting deficiencies in posterior pituitary hormones. Among the 24 PSIS patients, 12 had a history of growth hormone therapy before admission, and 12 had no such history. Additionally, 19 cases (79.2%) with PSIS were complicated by dyslipidemia, 15 cases (62.5%) were complicated by nonalcoholic fatty liver disease, and 9 cases (37.5%) were complicated by hyperuricemia.

Conclusions: PSIS often presents with growth retardation and hypogonadotropic hypogonadism, but in some cases, short stature is not exhibited. PSIS is prone to complications such as dyslipidemia, nonalcoholic fatty liver disease, and hyperuricemia, increasing the risk of cardiovascular and cerebrovascular diseases. In clinical practice, the diagnostic ability of PSIS should be improved, and pituitary function and complications should be evaluated in a timely manner to avoid delayed treatment.

References

Zhang W, Qian F, Lu G, Wu Y, Li R, Xia L . Pituitary stalk interruption syndrome: A rare case report and literature review. Medicine (Baltimore). 2020; 99(50):e23266. PMC: 7738060. DOI: 10.1097/MD.0000000000023266. View

Deng N, Mallepally N, Peng F, Kanji A, Marcelli M, Hernaez R . Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review. Liver Int. 2021; 41(10):2358-2370. DOI: 10.1111/liv.14938. View

Meng Q, Chao Y, Zhang S, Ding X, Feng H, Zhang C . Attenuation of estrogen and its receptors in the post-menopausal stage exacerbates dyslipidemia and leads to cognitive impairment. Mol Brain. 2023; 16(1):80. PMC: 10662842. DOI: 10.1186/s13041-023-01068-0. View

Wang C, Wei Q, Guo L, Liu H, Guo Q . Normal height and novel mutations in growth hormone deficiency adults with pituitary stalk interruption syndrome. Neuro Endocrinol Lett. 2020; 40(7-8):299-304. View

Huang Q, Xu H, Wang X, Mao J, Yu B, Zhu Y . Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. Clin Endocrinol (Oxf). 2022; 97(5):612-621. DOI: 10.1111/cen.14732. View

Dong X, Yao Z, Hu Y, Yang N, Gao X, Xu Y . Potential harmful correlation between homocysteine and low-density lipoprotein cholesterol in patients with hypothyroidism. Medicine (Baltimore). 2016; 95(29):e4291. PMC: 5265788. DOI: 10.1097/MD.0000000000004291. View

Zhu H, Xu Y, Gong F, Shan G, Yang H, Xu K . Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults. PLoS One. 2017; 12(10):e0185561. PMC: 5627923. DOI: 10.1371/journal.pone.0185561. View

Desideri G, Bocale R, DAmore A, Carnassale G, Necozione S, Barini A . Thyroid hormones modulate uric acid metabolism in patients with recent onset subclinical hypothyroidism by improving insulin sensitivity. Intern Emerg Med. 2019; 15(1):67-71. DOI: 10.1007/s11739-019-02065-9. View

Bellentani S . The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017; 37 Suppl 1:81-84. DOI: 10.1111/liv.13299. View

10.

Wang W, Wang S, Jiang Y, Yan F, Su T, Zhou W . Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited. Clin Endocrinol (Oxf). 2015; 83(3):369-76. DOI: 10.1111/cen.12788. View

11.

Jaiswal V, Sawhney A, Nebuwa C, Borra V, Deb N, Halder A . Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Prog Cardiovasc Dis. 2024; 85:45-53. DOI: 10.1016/j.pcad.2024.04.001. View

12.

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey W . American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the.... Endocr Pract. 2022; 28(5):528-562. DOI: 10.1016/j.eprac.2022.03.010. View

13.

Yang H, Xu H, Wang L, Duan L, Gong F, Zhu H . Metabolic Profile and Echocardiographic Evaluation in Adults with Growth Hormone Deficiency. Horm Metab Res. 2022; 54(12):827-832. DOI: 10.1055/a-1941-8556. View

14.

He H, Li D . One Case of Pituitary Stalk Interruption Syndrome Associated with Liver Cirrhosis. Endocr Metab Immune Disord Drug Targets. 2023; 23(9):1229-1234. DOI: 10.2174/1871530323666230228110650. View

15.

Xiao Z, Liu H . The estrogen receptor and metabolism. Womens Health (Lond). 2024; 20:17455057241227362. PMC: 10903191. DOI: 10.1177/17455057241227362. View

16.

Diwaker C, Thadani P, Memon S, Sarathi V, Lila A, Arya S . Pituitary stalk interruption syndrome: phenotype, predictors, and pathophysiology of perinatal events. Pituitary. 2022; 25(4):645-652. DOI: 10.1007/s11102-022-01243-x. View

17.

Xiao J, Zhu C, Zhang X, Sun L, Gao C, Liang X . Associations among FT level, FT/FT ratio, and non-alcoholic fatty liver disease in Chinese patients with hypopituitarism. Endocr J. 2022; 69(6):659-667. DOI: 10.1507/endocrj.EJ21-0536. View

18.

Mandal A, Leask M, Sumpter N, Choi H, Merriman T, Mount D . Genetic and Physiological Effects of Insulin-Like Growth Factor-1 (IGF-1) on Human Urate Homeostasis. J Am Soc Nephrol. 2023; 34(3):451-466. PMC: 10103387. DOI: 10.1681/ASN.0000000000000054. View

19.

Sesti G, Hribal M, Procopio T, Fiorentino T, Sciacqua A, Andreozzi F . Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr Metab Cardiovasc Dis. 2014; 24(12):1365-72. DOI: 10.1016/j.numecd.2014.06.012. View

20.

Tritos N . Growth hormone replacement in adults with cured acromegaly: Efficacy and safety. Best Pract Res Clin Endocrinol Metab. 2023; 37(6):101790. DOI: 10.1016/j.beem.2023.101790. View